-

Agilent LC/MS Instruments Receive ACT Labels from My Green Lab

Reinforcing Agilent’s commitment to sustainable innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.

“Agilent’s mission is to provide trusted answers and insights that advance the quality of life, and sustainability is an important part of achieving that mission,” said Sudharshana Seshadri, vice president of Agilent’s Mass Spectrometry Division. “We strive to consistently improve our sustainability through our innovative products and technologies that address complex issues in a sustainable way.”

Agilent is committed to helping labs meet their sustainability goals by including environmental considerations as drivers for innovation. In a recent global survey, 87% of lab managers indicated that sustainability goals are important in running their labs. Additionally, 68% reported that further work is required to achieve their sustainability goals.

“Partnering with My Green Lab has provided us the opportunity to work with an expert in this field,” said Darlene Solomon, senior vice president, and chief technology officer at Agilent. “We chose them for their holistic approach to sustainability and their understanding of the scientific interconnectivity across the laboratory, from chemicals to instruments to the environment itself.”

To celebrate these green instruments and also acknowledge Earth Day Agilent has kicked off a Plant a Tree program with customers and employees, with the goal to plant over 1,500 trees in Brazil, China, Colombia, Kenya and Tanzania, Mexico, and the United States, by the end of September 2021.

Additional instruments that received My Green Lab ACT Labels in 2020 include the Agilent 1220 Infinity II LC System, the 1260 Infinity II LC System, and the 1290 Infinity II LC System.

The ACT Label criteria, known as the Environmental Impact Factor (EIF) criteria, were developed with industry input. Agilent instruments that have received the ACT Label include sustainability features such as reduced energy consumption, less material used per product, smaller packaging (improving shipping sustainability), as well as sustainable (recycled) product and packaging. All enabling customers to make better informed as well as sustainable choices for their lab.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...
Back to Newsroom